Murphy M J, Fushimi F, Parchment R E, Barberá-Guillem E
Hipple Cancer Research Center, Dayton, Ohio 45439-2092, USA.
Invest New Drugs. 1996;13(4):303-14. doi: 10.1007/BF00873136.
Human colony forming units (CFUs) from both malignant and hematopoietic tissues can be assayed in vitro in microcapillary cultures, an alternative cloning system to the Petri dish methodology. For technical reasons, microcapillary culture may be ideally suited for new drug screening by therapeutic index. To achieve the high output required by screening programs, automated quantitation of CFUs is required. Toward this end, this paper reports the development of a prototype CapScan, an image analysis system that uses a novel axial laser illumination system to detect tumor cell colonies and, with technical modifications, CFU-granulocyte-macrophage (CFU-GM) colonies in microcapillary cultures. As currently configured, the CapScan can quantify colonies grown in a rack of 18 microcapillary cultures in 30 minutes or less. The sensitivity and detection specificity of tumor cell colonies is >90% with a coefficient of variance of 5-40%, dependent upon colony number. Over a range of colony numbers, CapScan and manual colony counts showed a linear correlation > -0.9, and yielded identical results in assays of doxorubicin inhibition of clonogenic P388 cells. As an additional advantage, the growth kinetics of individual colonies can also be monitored with the CapScan, making distinctions between cytotoxic and cytostatic drugs possible; colonies of freshly isolated human tumor cells can also be quantified. Thus, a microcapillary-based human tumor cloning assay that tests for resistance and/or sensitivity to chemotherapeutic agents may be useful in drug development programs and may also facilitate the development of chemotherapy for individual patient tumors, especially when tumor availability is limited.
来自恶性和造血组织的人类集落形成单位(CFU)可在微毛细管培养中进行体外测定,这是一种替代培养皿方法的克隆系统。由于技术原因,微毛细管培养可能非常适合通过治疗指数进行新药筛选。为了实现筛选程序所需的高产量,需要对CFU进行自动定量。为此,本文报告了一种原型CapScan的开发,这是一种图像分析系统,它使用一种新型轴向激光照明系统来检测肿瘤细胞集落,并通过技术改进检测微毛细管培养中的CFU-粒细胞-巨噬细胞(CFU-GM)集落。按照目前的配置,CapScan可以在30分钟或更短时间内对18个微毛细管培养架中生长的集落进行定量。肿瘤细胞集落的灵敏度和检测特异性>90%,变异系数为5-40%,取决于集落数量。在一系列集落数量范围内,CapScan和手动集落计数显示线性相关性>-0.9,并且在阿霉素抑制克隆性P388细胞的测定中产生相同的结果。作为另一个优点,CapScan还可以监测单个集落的生长动力学,从而区分细胞毒性药物和细胞抑制药物;新鲜分离的人类肿瘤细胞集落也可以进行定量。因此,基于微毛细管的人类肿瘤克隆测定法可用于测试对化疗药物的耐药性和/或敏感性,这在药物开发计划中可能有用,也可能有助于为个体患者肿瘤开发化疗方案,特别是当肿瘤样本有限时。